Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients

Current HIV Research

Volumn 5, Issue 3, 2007, Pages 349-353

  Matteelli, Alberto ^a   Regazzi, Mario ^b   Villani, Paola ^b   De Iaco, Giuseppina ^a   Cusato, Maria ^b   Carvalho, Anna Cristina C ^a   Caligaris, Silvio ^a   Tomasoni, Lina ^a   Manfrin, Maria ^a   Capone, Susanna ^a   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Efavirenz; HIV infection; Pharmacokinetic interaction; Rifampicin

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ABNORMAL DREAMING; ADULT; AREA UNDER THE CURVE; BODY WEIGHT; CAUCASIAN; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION LOSS; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; REPEATED DRUG DOSE; REVIEW; SUPERINFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; BENZOXAZINES; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; RIFAMPIN; TUBERCULOSIS;

EID: 34249069242     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207780636588     Document Type: Review

References (17)

1. Badri M, Wilson D, Wood R. (2002). Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 359:2059-2064.
2. Barrett JS, Joshi AS, Chai M, Ludden TM, Fiscke WD, Pieniaszek HJ Jr. (2002). Population pharmacokinetic meta-analysis with efavirenz. International Journal of Clinical Pharmacology and Therapeutics. 40: 507-519.
3. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. (2005). Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS. 19: 1541-1546
4. Corbett EL, Watt C, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. (2003). The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine. 163: 1009-1021.
5. Department of Health and Human Services (DHHS). Panel on clinical practice for treatment of HIV infection. Guidelines for the use of antiretroviral agents it HIV-1 adults and adolescents. October 10, 2006. Available at http://AIDSinfo.nih.gov. Accessed November 22, 2006
6. Friedland G, Khoo S, Jack C, Lalloo, U. (2006). Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and IRV. Journal of Antimicrobial Chemotherapy. 58:1299-302.
7. Girardi E, Palmieri F, Cingolani A, Ammassari A, Petrosillo, N, Grillino N, Zinzi D, De Luca A, Antinori A, Ippolito G. (2001). Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome. 26:326-331
8. Glaeser H, Drescher S, Eichelbaum M, Fromm MF. (2004). Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. British Journal of Clinical Pharmacology. 59: 199-206.
9. Kolars JC, Schmiedlin-Ren, Schuetz JD, Fang C, Watkins PB. (1992). Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. Journal of Clinical Investigations. 90: 1871-1878.
10. Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F. (2006). Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. Journal of Antimicrobial Chemotherapy. 58:1017-23.
11. Lopez-Cortez LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzales A, Gomez-Mateos J, Leon-Jimenez E, Sarasa-Nacenta M, Lopez-Pua Y, Pachon J. (2002). Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clinical Pharmacokinetic. 41: 681-690.
12. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, Prasithsirikul W, Sankote J, Mahanontharit A, Ruxrungtham K. (2005). Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS. 19: 1481-1486.
13. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham Y, Vibhagool A, Rattanasiri S, Thakkinstian A. (2006). Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 20: 131-132.
14. Marzolini C, Telenti A, Decostersd LA, Greub G, Biollaz J, Buclin T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS. 15:71-75.
15. US national centre for HIV, STD and TB prevention - Division of TB elimination. Updated guidelines for the use of rifamycines for the treatment of tuberculosis among HIV infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. 20 Jan 2004. Available from URL: http//www.cdc.gov/nchstp/th/tb_hiv_drugs/ toc.htm. Accessed November 22, 2006
16. Villani P, Regazii MB, Castelli F, Viale P, Torti C, Seminari E, Maserati R. (1999). Pharmacokinetics of efavirenz (EFV) alone or in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. British Journal of Clinical Pharmacology. 48: 712-715.
17. World Health Organization (WHO). Antiretroviral therapy for H[V infection in adults and adolescents in resource limited settings: towards universal access. Recommendations for a public health approach. 2006 revision. Geneva, WHO, 2006. Available from URL: http//www.who.int/ 3by5/publications/documents/arv_guidelines/en/ Accessed on November 22, 2006.